Biomarker in Lung Diseases

The recruitment status of this study is unknown because the information has not been verified recently.
Verified October 2009 by Heidelberg University.
Recruitment status was  Recruiting
Information provided by:
Heidelberg University Identifier:
First received: October 5, 2009
Last updated: October 13, 2009
Last verified: October 2009

Disease related biomarkers have been established decades ago, e.g. blood glucose for diabetes diagnosis and management. Their discovery has grown dramatically during the past decade and they have the potential to lead the physician in diagnosis -especially differential diagnosis - and therapy.

However, a specific serum-biomarker in lung diseases has not been established. Aim of the current study is to to measure lung specific proteins in the serum in patients with various lung diseases and to correlate those with disease severity, lung function and other laboratory results

Condition Intervention
Lung Diseases
Other: biomarker

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Feasibility Study on Establishing Biomarkers in Lung Diseases

Resource links provided by NLM:

Further study details as provided by Heidelberg University:

Primary Outcome Measures:
  • Serum biomarker expression [ Time Frame: 1 month ] [ Designated as safety issue: No ]

Biospecimen Retention:   Samples Without DNA
Serum (blood)

Estimated Enrollment: 120
Study Start Date: October 2009
Estimated Study Completion Date: June 2010
Estimated Primary Completion Date: March 2010 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
lung disease
patients with various chronic or acute lung diseases
Other: biomarker
measuring serum-biomarkers


Ages Eligible for Study:   18 Years to 90 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patients with acute or chronic lung diseases

Inclusion Criteria:

  • age >= 18
  • acute or chronic lung disease

Exclusion Criteria:

  • HIV
  • lactation or gestation
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00989846

Contact: Michael Kreuter, MD 49 / 6221 / 396 ext 1201

Thoraxklinik Heidelberg, Dept. of Pneumology and Respiratory Critical care Recruiting
Heidelberg, Germany, 69126
Contact: Michael Kreuter, MD    49 / 6221 / 396 ext 1201   
Principal Investigator: Michael Kreuter, MD         
Sponsors and Collaborators
Heidelberg University
Principal Investigator: Michael Kreuter, MD Thoraxklinik Heidelberg, Germany
Study Director: Felix JF Herth, MD Thoraxklinik Heidelberg Germany
  More Information

Responsible Party: Dr. Michael Kreuter, Thoraxklinik Heidelberg Identifier: NCT00989846     History of Changes
Other Study ID Numbers: MK02
Study First Received: October 5, 2009
Last Updated: October 13, 2009
Health Authority: Germany: Federal Institute for Drugs and Medical Devices

Keywords provided by Heidelberg University:
lung disease

Additional relevant MeSH terms:
Lung Diseases
Respiratory Tract Diseases processed this record on November 25, 2015